Literature DB >> 17650444

FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.

Emanuela Carlotti1, Giuseppe A Palumbo, Elena Oldani, Daniele Tibullo, Silvia Salmoiraghi, Andrea Rossi, Josee Golay, Alessandro Pulsoni, Robin Foà, Alessandro Rambaldi.   

Abstract

We analyzed FcgammaRIIIA-158V/F and FcgammaRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP and Rituximab. With a median follow-up of 5.8 years, the overall survival at 8 years is 83%. Univariate and multivariate analysis showed no correlation between FcgammaRIIIA-158VV/VF and FcgammaRIIA-131HH/HR polymorphisms and the overall response rate, the molecular response and the event-free survival obtained after CHOP and Rituximab. By contrast, the achievement of a durable molecular clearance of BCL2/IgH+ cells detectable in the bone marrow is confirmed to be a reliable predictive factor of a better long-term clinical outcome.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17650444     DOI： 10.3324/haematol.11288

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  42 in total

1.  Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.

Authors:  Daniel O Persky; David Dornan; Bryan H Goldman; Rita M Braziel; Richard I Fisher; Michael Leblanc; David G Maloney; Oliver W Press; Thomas P Miller; Lisa M Rimsza
Journal:  Haematologica       Date:  2012-01-22       Impact factor: 9.941

2.  Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.

Authors:  Sara A Hurvitz; David J Betting; Howard M Stern; Emmanuel Quinaux; Jeremy Stinson; Somasekar Seshagiri; Ying Zhao; Marc Buyse; John Mackey; Adrian Driga; Sambasivarao Damaraju; Mark X Sliwkowski; Nicholas J Robert; Vicente Valero; John Crown; Carla Falkson; Adam Brufsky; Tadeusz Pienkowski; Wolfgang Eiermann; Miguel Martin; Valerie Bee; Omkar Marathe; Dennis J Slamon; John M Timmerman
Journal:  Clin Cancer Res       Date:  2012-04-13       Impact factor: 12.531

Review 3.  Rituximab: mechanism of action.

Authors:  George J Weiner
Journal:  Semin Hematol       Date:  2010-04       Impact factor: 3.851

4.  Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol.

Authors:  László Váróczy; Erika Zilahi; Agnes Gyetvai; Béla Kajtár; Lajos Gergely; Sándor Sipka; Arpád Illés
Journal:  Pathol Oncol Res       Date:  2011-06-14       Impact factor: 3.201

Review 5.  Host genetics in follicular lymphoma.

Authors:  James R Cerhan
Journal:  Best Pract Res Clin Haematol       Date:  2011-05-05       Impact factor: 3.020

Review 6.  Rituximab resistance.

Authors:  Andrew R Rezvani; David G Maloney
Journal:  Best Pract Res Clin Haematol       Date:  2011-04-13       Impact factor: 3.020

7.  Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.

Authors:  Rodney J Taylor; Vassiliki Saloura; Ajay Jain; Olga Goloubeva; Stuart Wong; Shari Kronsberg; Madhavi Nagilla; Lorna Silpino; Jonas de Souza; Tanguy Seiwert; Everett Vokes; Victoria Villaflor; Ezra E W Cohen
Journal:  Cancer Immunol Res       Date:  2015-03-13       Impact factor: 11.151

8.  Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.

Authors:  Robert A Baiocchi; Lapo Alinari; Mark E Lustberg; Thomas S Lin; Pierluigi Porcu; Xiaobai Li; Jeffrey S Johnston; John C Byrd; Kristie A Blum
Journal:  Cancer       Date:  2010-12-14       Impact factor: 6.860

Review 9.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

Review 10.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.